SCHEMBL22805925

SCHEMBL22805925

COc1ccc(CNc2nc(NCCN)nc3c2cnn3C)cc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ BCDIN3D Q7Z5W3 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487096 1.00 BCDIN3D (1.00) BCDIN3D
SCHEMBL29582313 0.92 BCDIN3D (1.00) BCDIN3D
SCHEMBL22806417 0.92 BCDIN3D (1.00) BCDIN3D
SCHEMBL22805928 0.87 BCDIN3D (1.00) BCDIN3D
SCHEMBL29582651 0.87 BCDIN3D (1.00) BCDIN3D
SCHEMBL22805339 0.87 BCDIN3D (1.00) BCDIN3D
SCHEMBL29582699 0.87 BCDIN3D (1.00) BCDIN3D
SCHEMBL22823997 0.87 BCDIN3D (1.00) BCDIN3D
SCHEMBL29487198 0.87 BCDIN3D (1.00) BCDIN3D
SCHEMBL22806448 0.86 BCDIN3D (1.00) BCDIN3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220370453-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY STORM THERAPEUTICS LIMITED (GB) 2022-11-24 — — US claimed
EP-3986568-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY Storm Therapeutics Ltd (GB) 2022-04-27 — — EP claimed
CN-114286711-A Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity 风暴治疗有限公司 2022-04-05 — — CN claimed
WO-2020254831-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY STORM THERAPEUTICS LTD (GB) 2020-12-24 — — WO claimed
US-20220370453-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY STORM THERAPEUTICS LIMITED (GB) 2022-11-24 — — US disclosed
EP-3986568-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY Storm Therapeutics Ltd (GB) 2022-04-27 — — EP disclosed
CN-114286711-A Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity 风暴治疗有限公司 2022-04-05 — — CN disclosed
WO-2020254831-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY STORM THERAPEUTICS LTD (GB) 2020-12-24 — — WO disclosed
WO-2020254831-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY STORM THERAPEUTICS LTD (GB) 2020-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370453-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BCDIN3D ACTIVITY BCDIN3D, CDK3, CCNI BCDIN3D 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback